Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2021 | 3 |
2022 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
RMD Open. 2022 Sep;8(2):e002423. doi: 10.1136/rmdopen-2022-002423.
RMD Open. 2022.
PMID: 36180101
Free PMC article.
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R.
Fleischmann RM, et al. Among authors: bock ae.
Arthritis Res Ther. 2021 Sep 25;23(1):248. doi: 10.1186/s13075-021-02626-4.
Arthritis Res Ther. 2021.
PMID: 34563243
Free PMC article.
Clinical Trial.
Item in Clipboard
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
Fleischmann RM, Bock AE, Zhang W, Godfrey CM, Vranic I, Cronenberger C, Dokoupilová E.
Fleischmann RM, et al. Among authors: bock ae.
Rheumatol Ther. 2022 Jun;9(3):839-850. doi: 10.1007/s40744-022-00439-8. Epub 2022 Mar 18.
Rheumatol Ther. 2022.
PMID: 35304684
Free PMC article.
Item in Clipboard
Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Cox DS, Alvarez DF, Bock AE, Cronenberger CL.
Cox DS, et al. Among authors: bock ae.
Clin Pharmacol Drug Dev. 2021 Oct;10(10):1166-1173. doi: 10.1002/cpdd.939. Epub 2021 Mar 25.
Clin Pharmacol Drug Dev. 2021.
PMID: 33765358
Free PMC article.
Clinical Trial.
Item in Clipboard
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R.
Fleischmann RM, et al. Among authors: bock ae.
RMD Open. 2021 Apr;7(2):e001578. doi: 10.1136/rmdopen-2021-001578.
RMD Open. 2021.
PMID: 33883254
Free PMC article.
Clinical Trial.
Item in Clipboard
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, Alvarez D, Bock AE, Sewell KL.
Fleischmann RM, et al. Among authors: bock ae.
Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y.
Arthritis Res Ther. 2018.
PMID: 30111357
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite